Related Experiment Video
Updated: Apr 25, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.2K
Metformin and gynecologic cancers.
Jessica E Stine1, Victoria Bae-Jump2
1Gynecologic Oncology Fellow, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC.
Obstetrical & Gynecological Survey
|August 22, 2014
Summary
Metformin, a diabetes drug, shows promise in preventing and treating gynecologic cancers, particularly in obese patients. Ongoing clinical trials are exploring its effectiveness against endometrial and ovarian cancers.
Area of Science:
- Oncology
- Pharmacology
- Epidemiology
Background:
- Obesity is a significant risk factor and prognostic marker for gynecologic cancers.
- Novel treatment strategies targeting obese populations are crucial for improving outcomes.
- Metformin, a common diabetes medication, is being investigated for its potential anticancer properties.
Purpose of the Study:
- To review the biological mechanisms behind metformin's antitumor effects.
- To assess preclinical and epidemiological data supporting metformin use in endometrial and ovarian cancers.
- To examine current clinical trials investigating metformin in gynecologic cancer prevention and treatment.
Main Methods:
- Comprehensive literature search of PubMed for relevant studies.
- Evaluation of preclinical, clinical, and epidemiological data.
- Focus on gynecologic cancer, including endometrial and ovarian malignancies.
Main Results:
- Preclinical, epidemiological, and clinical data strongly support metformin's role in gynecologic cancer prevention and treatment.
- Clinical trials are actively enrolling patients with gynecologic malignancies to evaluate metformin.
- Evidence indicates metformin's potential benefits in managing these cancers.
Conclusions:
- Growing evidence supports metformin's use in preventing and treating gynecologic cancers like endometrial and ovarian cancer.
- Metformin is an attractive therapeutic agent due to its potential to counteract obesity-related risks and improve outcomes.
- Further research and clinical trials are warranted to solidify metformin's role in gynecologic oncology.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
987
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
987
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
947
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
947
01:24Disorders of the Female Reproductive System
4.5K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.5K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
4.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K